Form 4: Alignment Healthcare CEO Sells Shares for Tax, 10b5-1 Plan

Alignment Healthcare CEO John E. Kao reported the sale of 535,018 shares of common stock, primarily to cover tax withholding obligations from restricted stock unit vesting and through a pre-arranged 10b5-1 plan.

Summary

• John E. Kao, CEO and Director of Alignment Healthcare, Inc. (ALHC), reported the sale of 535,018 shares of common stock.
• The transactions occurred on September 10, 2025.
• 253,908 shares were sold at a weighted-average price of $16.2293, with prices ranging from $15.74 to $16.735.
• 101,110 shares were sold at a weighted-average price of $16.8555, with prices ranging from $16.74 to $17.24.
• An additional 180,000 shares were sold at a weighted-average price of $16.4164, with prices ranging from $16.03 to $16.73.
• The sales related to 253,908 and 101,110 shares were non-discretionary, executed to cover tax withholding obligations from restricted stock unit vesting.
• The sale of 180,000 shares was conducted under a Rule 10b5-1 trading plan adopted on March 12, 2025.
• Following these transactions, Mr. Kao directly beneficially owns 4,533,568 shares and indirectly owns 1,193,100 shares through the JEK Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a concern, the filing clearly states that a significant portion was for tax withholding on RSU vesting, which is a routine event. The remaining sale was under a 10b5-1 plan, indicating a pre-scheduled, non-discretionary sale. This mitigates the negative perception of insider selling.

Positives

• The majority of the sales (355,018 shares) were non-discretionary, specifically to cover tax withholding obligations related to RSU vesting, indicating a routine compensation event rather than a discretionary divestment.
• The remaining sale (180,000 shares) was executed under a pre-arranged Rule 10b5-1 plan, which suggests a planned, non-opportunistic sale.

Negatives

• Significant insider selling by the CEO, totaling 535,018 shares, could be perceived negatively by investors, regardless of the stated reasons.

Risks

• Investor sentiment could be negatively impacted by the perception of insider selling, potentially leading to short-term stock price volatility.
• While explained as non-discretionary or pre-planned, large insider sales can sometimes be misinterpreted as a lack of confidence in the company's future prospects.

Corporate Governance

Related Party Transactions

• John E. Kao indirectly holds 1,193,100 shares through the JEK Trust, dated February 8, 2021, of which he is the trustee.

Stakeholder Impact

• Shareholders may react to the news of significant insider selling, potentially leading to short-term price fluctuations, despite the stated reasons for the sales.
• The transparency provided by the Form 4 and the explanation of tax-related and 10b5-1 plan sales helps inform investors about the nature of these transactions.

Key Dates

Keywords

Alignment Healthcare, ALHC, John E. Kao, Insider Trading, Form 4, Stock Sale, CEO, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan, Healthcare Technology